At-home self-injection therapy for inflammatory skin lesions — a clinical-grade microneedle pen (ClearPen) delivering triamcinolone acetonide, distributed through telemedicine and manufactured under a Lifecore Biomedical drug/device agreement Web.
Indomo takes a fifty-year-old, dermatologist-administered corticosteroid injection — still first-line for inflamed acne per the AAD — and re-packages it as a consumer-usable pen delivered through telehealth, opening a category with no incumbent at-home injectable and a clear roadmap into keloids and hidradenitis suppurativa. The Series B is tranched: $15M B-1 already funded at $35M pre / $50M post, and a $7M B-2 tranche steps up to $68M pre / $75M post on positive Phase 2 interim data expected end of Q1 2026 Internal. Foresite Capital leads with $12M and Polaris and Atomic take the balance inside — a Tier-1 healthcare syndicate typically reserved for category-defining assets. StoryHouse Fund I holds 1.72% and is offered legal pro rata of $63.6K into B-2; the return case rests on the Phase 2 readout and on whether AbbVie, Galderma, Johnson & Johnson, or Bausch treat this as a strategic aesthetic-dermatology asset once the Phase 2 data lands.
Indomo does not need to move the entire $9B global acne market — the initial wedge is the sub-segment of patients with active inflammatory lesions who today either accept scarring or make an in-office dermatology visit for an intralesional triamcinolone injection. That behavior is an AAD first-line recommendation but supply-constrained by dermatologist capacity. The label-expansion targets Indomo has publicly named — keloids and hidradenitis suppurativa Web — sit inside a multi-billion self-administered biologics category and open the microneedle platform into severity segments where willingness-to-pay is materially higher.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Indomo (ClearPen) | At-home microneedle pen + triamcinolone acetonide, telehealth channel, Lifecore CMO Internal | Series B2 · $22M total · $75M post | — |
| Cutera (AviClear) | 1,726nm in-office laser for acne on all severities and skin types Web | Public (NASDAQ: CUTR) | Capital-equipment channel via dermatology offices; not at-home; same lesion population |
| Accure Laser | 1,726nm selective photothermolysis acne laser in trials Web | Private | In-office energy device; same channel dependency as AviClear |
| Galderma | Topicals, aesthetic biologics, category incumbent in derm Web | Public (SIX: GALD) | Incumbent with distribution; more plausible acquiror than direct competitor |
| AbbVie (Skyrizi, Rinvoq; +Apogee) | Systemic biologics for inflammatory skin disease; June 2026 Apogee acquisition for $10.9B added IL-13 derm asset Web | Public (NYSE: ABBV) | Systemic biologic vs. localized injection; complementary; likely strategic acquiror |
| Hims & Hers / consumer telederm | Rx topicals + oral acne via subscription Web | Public (NYSE: HIMS) | Channel analog and potential partner — Cara Davis and Jack Abraham come from this playbook |
Moat: First-mover in a regulated at-home injection modality with a bundled drug/device NDA path and a signed Lifecore Biomedical manufacturing agreement Web — a combination that is hard to reverse-engineer without both dermatology-trial infrastructure and consumer-grade device design. Downstream, the microneedle platform ports to keloids and HS, which raises switching cost for any strategic entering self-administered dermatology.
Strategic acquisition by a dermatology or aesthetics pharma post-Phase 2 or post-Phase 3 is the base case; a $225M–$300M exit clears a 3–4x return from a $75M entry, and a $750M+ outcome (10x) requires successful expansion into keloids/HS or a strategic willing to underwrite the consumer telehealth channel.
Named acquirors & comps. AbbVie’s June 2026 $10.9B acquisition of Apogee Therapeutics for atopic-dermatitis biologic APG777 confirms IL-13/dermatology remains a top capital-allocation priority for big pharma Web. Galderma (SIX-listed since 2024) and Bausch Health remain natural derm consolidators; Johnson & Johnson and Pfizer are the standing category acquirors Web. On the aesthetics side, Cutera is a potential horizontal combiner given the overlapping acne target population.
Rick clarified SH allocation sits at $400–425K; Polaris (Gary) is supportive of getting SH to a full check via secondary if needed, and Rick/Polaris will guarantee access to the B-2 tranche to close the $75–100K gap. Weighted-average share price moves 3–6% by biasing toward B-2 pricing.
Rick relayed Goodwin’s clearance for ~$433K available to SH; SH pushed for the full $500K, and Rick opened alternate paths (secondaries, waiting on Gaingels / Josh Jones sizing) to close the gap. Capital needed by May 28.
$22M total round led by Foresite ($12M) at $75M post; structured as a two-tranche priced round with B-1 at $35M pre / $50M post and B-2 at $68M pre triggered by positive Phase 2 interim data end of Q1 2026. Remaining $10M split between Atomic and Polaris. SH holds 1.72%; legal pro rata is $378K blended.